Multiple Myeloma Clinical Trials


High Dose Chemotherapy Using BeEAM for Autologous Transplant in Multiple Myeloma

High-dose chemotherapy and autologous stem cell transplantation (ASCT) as part of the up-front treatment of patients with multiple myeloma has been associated with improved disease-free and overall survival in multiple large ra...

Learn More

Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma ((Mel/MelVel))

High dose chemotherapy with stem cell transplantation is commonplace in the treatment of multiple myeloma. This treatment uses a chemotherapy drug called Melphalan that has been used in severalthousand bone marrow transplant recipients w...

Learn More

Prospective Observational Study of Clinical and Genomic Predictors of Progression to Myeloma in Asymptomatic Monoclonal Gammopathies

The goal of this clinical research study is to find markers that might help predict why some patients with monoclonal gammopathy of unknown significance (MGUS) and smoldering multiple myeloma (SMM) develop multiple myeloma, while ot...

Learn More

NY-ESO-1?²??T Alone and in Combination With Pembrolizumab for Multiple Myeloma

Conditions:   Multiple Myeloma;   Refractory Multiple Myeloma
Interventions:   Genetic: NY-ESO-1?²??T cells;   Drug: NY-ESO-1?²??T in combination with pembrolizumab
Sponsors:   Adaptimmune;   Merck Sharp & Dohme Corp.;   GlaxoSmithKline
Not yet recruiting - verified May 2017

Learn More

2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma

Condition:   Multiple Myeloma
Interventions:   Drug: Elotuzumab;   Drug: Lenalidomide;   Drug: Dexamethasone;   Drug: Bortezomib
Sponsor:   University of Arkansas
Not yet recruiting - verified May 2017

Learn More

Phase I Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma

Conditions:   Multiple Myeloma;   Immune System Diseases
Intervention:   Drug: CAR138 T Cells
Sponsor:   UNC Lineberger Comprehensive Cancer Center
Not yet recruiting

Learn More

First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody

Condition:   Multiple Myeloma
Interventions:   Drug: 89Zr-daratumumab;   Device: PET/CT scans;   Other: Blood draws
Sponsor:   Memorial Sloan Kettering Cancer Center
Recruiting

Learn More

Safety and Efficacy of ABI-009 (Nab-rapamycin) in Combination With Pomalidomide and Dexamethasone for Relapsed and Refractory Multiple Myeloma

Condition:   Multiple Myeloma
Interventions:   Drug: ABI-009;   Drug: Pomalidomide;   Drug: Dexamethasone
Sponsors:   Massachusetts General Hospital;   Aadi, LLC
Not yet recruiting

Learn More

T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple Myeloma

Conditions:   Myeloma-Multiple;   Myeloma, Plasma-Cell
Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: Anti-BCMA CAR T cells
Sponsor:   National Cancer Institute (NCI)
Recruiting

Learn More

Therapeutic Use of Intravenous Vitamin C in Allogeneic Stem Cell Transplant Recipients

Conditions:   Hodgkin Lymphoma;   Lymphoid Leukemia;   Multiple Myeloma;   Myeloid Leukemia;   Monocytic Leukemia;   Non Hodgkin Lymphoma;   Myelodysplasia
Intervention:   Drug: Intravenous (IV) and oral Vitamin C
Sponsor:   Virginia Commonwealth University
Not yet recruiting

Learn More

A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Condition:   Multiple Myeloma
Interventions:   Drug: Venetoclax;   Drug: Pomalidomide;   Drug: Dexamethasone
Sponsors:   AbbVie;   Celgene
Not yet recruiting

Learn More

A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Subjects With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody

Condition:   Multiple Myeloma
Interventions:   Drug: GSK2857916 frozen;   Drug: GSK2857916 lyophilized;   Other: NEI-VFQ-25 Questionnaire;   Other: OSDI Questionnaire;   Other: EORTC QLQ-C30 Questionnaire;   Other: EORTC QLQ-MY20 Questionnaire
Sponsor:   GlaxoSmithKline
Recruiting

Learn More

MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma

Condition:   Relapsed/Refractory Multiple Myeloma
Interventions:   Biological: Dose Escalation, MEDI2228, ADC (antibody drug conjugate);   Biological: Dose Expansion, MEDI2228, ADC (antibody drug conjugate)
Sponsor:   MedImmune LLC
Recruiting

Learn More

Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma

Condition:   Multiple Myeloma
Intervention:   Drug: CC-93269
Sponsor:   Celgene
Recruiting

Learn More

Autologous CD8+ T-cells Transiently Expressing an Anti-BCMA CAR in Patients With Myeloma

Condition:   Multiple Myeloma
Intervention:   Biological: Descartes-08
Sponsor:   Cartesian Therapeutics
Recruiting

Learn More

1-15 of 52
Results per page

Join the community!


You must be a member of healtheo360 in order to view this group

Register with Email Address

Already a member? Click here to login

healtheo360 believes strongly in user privacy.